← all works
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Canadian affiliationAn author listed a Canadian institution. This is the only route the usual frame has.
Abstract
No abstract. This is not a gap in this database — OpenAlex has none either. 23.3% of the frame is in this state, and the screen finds HALF as much metaresearch here, so the absence is a measured bias rather than a missing field.
The record
- Venue
- The Lancet
- Topic
- CAR-T cell therapy research
- Field
- Medicine
- Canadian institutions
- Princess Margaret Cancer CentreUniversity Health Network
- Funders
- Janssen Research and Development
- Keywords
- Chimeric antigen receptorAntigenRefractory (planetary science)MedicineOpen labelMultiple myelomaReceptorImmunologyCellImmunotherapyCancer researchBiologyInternal medicineImmune systemClinical trial
- Has abstract in OpenAlex
- no